Erratum: The Sierra Leone trial to introduce a vaccine against ebola: An evaluation of rVSVΔG-ZEBOV-GP vaccine tolerability and safety during the west Africa ebola outbreak (Journal of Infectious Diseases (2018) 217 (S6-S15) DOI: 10.1093/infdis/jiy020);The Sierra Leone Trial to Introduce a Vaccine Against Ebola: An Evaluation of rVSVΔG-ZEBOV-GP Vaccine Tolerability and Safety during the West Africa Ebola Outbreak

Journal of Infectious Diseases

Volumn 217, Issue , 2018, Pages S6-S15

  Samai, Mohamed ^a   Seward, Jane F ^a,f   Goldstein, Susan T ^b   Mahon, Barbara E ^b   Lisk, Durodami Radcliffe ^a   Widdowson, Marc Alain ^b   Jalloh, Mohamed I ^a   Schrag, Stephanie J ^b   Idriss, Ayesha ^a   Carter, Rosalind J ^b   Dawson, Peter ^c   Kargbo, S A S ^a   Leigh, Bailah ^a   Bawoh, Mohamed ^a   Legardy Williams, Jennifer ^b   Deen, Gibrilla ^a   Carr, Wendy ^b   Callis, Amy ^b,g   Lindblad, Robert ^c   Russell, James B W ^a   Petrie, Carey R ^c   Fombah, Augustin E ^a   Kargbo, Brima ^d   McDonald, Wendi ^a,h   Jarrett, Olamide D ^a,i   Walker, Robert E ^e   Gargiullo, Paul ^b   Bash Taqi, Donald ^a   Gibson, Laura ^e   Fofanah, Abu Bakarr ^d   Schuchat, Anne ^b   Neuzil, Kathleen ^j   Insip, Hazel ^j   Risi, George ^j   Sow, Samba ^j   more..

^a University of Freetown   (Sierra Leone)

^b CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^c EMMES CORPORATION   (United States)

^d MINISTRY OF HEALTH AND SANITATION   (Sierra Leone)

^e U S DEPARTMENT OF HEALTH AND HUMAN SERVICES   (United States)

^f Task Force for Global Health   (United States)

^g Devi Partners   (United States)

^h Pharmaceutical Product Development   (United States)

ⁱ UNIVERSITY OF ILLINOIS   (United States)

^j NONE

more..

Author keywords

clinical trial; Ebola; safety; serious adverse events; vaccine

Indexed keywords

EBOLA VACCINE; RECOMBINANT VACCINE;

ABDOMINAL PAIN; ADULT; AGED; ARTHRALGIA; ARTICLE; CHILL; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIARRHEA; DISEASE SEVERITY; DRUG EFFICACY; DRUG MONITORING; DRUG SAFETY; DRUG SCREENING; DRUG TOLERABILITY; EBOLA HEMORRHAGIC FEVER; EPIDEMIC; FATIGUE; FEMALE; FEVER; FOLLOW UP; HEADACHE; HUMAN; JOINT SWELLING; MAJOR CLINICAL STUDY; MALE; MOUTH ULCER; MYALGIA; NAUSEA; PAIN; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; SIERRA LEONE; SKIN REDNESS; SYSTEMIC DISEASE; TREATMENT DURATION; TREATMENT PLANNING; VACCINATION; VOMITING; WEST AFRICAN; ADOLESCENT; ADVERSE DRUG REACTION; CLINICAL TRIAL; LONGITUDINAL STUDY; MIDDLE AGED; PATHOLOGY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; EBOLA VACCINES; EPIDEMICS; FEMALE; HEMORRHAGIC FEVER, EBOLA; HUMANS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; SIERRA LEONE; VACCINES, SYNTHETIC; YOUNG ADULT;

EID: 85047524367     PISSN: 00221899     EISSN: 15376613     Source Type: Journal    
DOI: 10.1093/infdis/jiy353     Document Type: Erratum

References (32)

1. Gostin LO, Lucey D, Phelan A. The Ebola epidemic: a global health emergency. JAMA 2014; 312:1095-6.
2. Incident Management System Ebola Epidemiology Team CDC, Guinea Interministerial Committee for Response Against the Ebola Virus, CDC Guinea Response Team, et al. Update: Ebola virus disease outbreak-West Africa, October 2014. MMWR Morb Mortal Wkly Rep 2014; 63:978-81.
3. Kilmarx PH, Clarke KR, Dietz PM, et al. Ebola virus disease in health care workers - Sierra Leone, 2014. MMWR Morb Mortal Wkly Rep 2014; 63:1167-71.
4. World Health Organization. Meeting Summary of the WHO Consultation on Potential Ebola Therapies and Vaccines. Geneva, Switzerland: World Health Organization; 2014.
5. Geisbert TW, Feldmann H. Recombinant vesicular stomatitis virus-based vaccines against Ebola and Marburg virus infections. J Infect Dis 2011; 204(Suppl 3):S1075-81.
6. Agnandji ST, Huttner A, Zinser ME, et al. Phase 1 Trials of rVSV Ebola vaccine in Africa and Europe. N Engl J Med 2016; 374:1647-60.
7. Henao-Restrepo AM, Longini IM, Egger M, et al. Efficacy and effectiveness of an rVSV-vectored vaccine expressing Ebola surface glycoprotein: interim results from the Guinea ring vaccination cluster-randomised trial. Lancet 2015; 386:857-66.
8. Widdowson MA, Schrag SJ, Carter RJ, et al. Implementing an Ebola Vaccine Study-Sierra Leone. MMWR Suppl 2016; 65:98-106.
9. Soares JF, Wu CFJ. Some restricted randomization rules in sequential designs. Commun Stat Theory Methods 1983; 12:2017-34.
10. Zhao W, Weng Y, Wu Q, Palesch Y. Quantitative comparison of randomization designs in sequential clinical trials based on treatment balance and allocation randomness. Pharm Stat 2012; 11:39-48.
11. Garbutt M, Liebscher R, Wahl-Jensen V, et al. Properties of replication-competent vesicular stomatitis virus vectors expressing glycoproteins of filoviruses and arenaviruses. J Virol 2004; 78:5458-65.
12. Merck and Co., Inc. Investigator's Brochure. V920. 4 December 2015. Edition 2.
13. Guidance for Industry and Investigators: Safety Reporting Requirements for INDs and BA/BE Studies. Silver Spring, MD: Food and Drug Administration, 2012.
14. World Health Organization. Verbal autopsy standards: the 2014 WHO verbal autopsy instrument. 2014. http://www.who.int/healthinfo/statistics/verbalau topsystandards/en/index1.html. Accessed 10 January 2018.
15. Conteh MA, Goldstein ST, Lisk DR, et al. Clinical surveillance and evaluation of suspected Ebola cases in a vaccine trial during an Ebola epidemic: the Sierra Leone Trial to Introduce a Vaccine Against Ebola (STRIVE). J Infect Dis 2018; 217:s33-9.
16. Huttner A, Dayer JA, Yerly S, et al. The effect of dose on the safety and immunogenicity of the VSV Ebola candidate vaccine: a randomised double-blind, placebo-controlled phase. trial. Lancet Infect Dis 2015; 15:1156-66.
17. Kennedy SB, Neaton JD, Lane HC, et al. Implementation of an Ebola virus disease vaccine clinical trial during the Ebola epidemic in Liberia: design, procedures, and challenges. Clin Trials 2016; 13:49-56.
18. Ebola ca Suffit Ring Vaccination Trial Consortium. The ring vaccination trial: a novel cluster randomised controlled trial design to evaluate vaccine efficacy and effectiveness during outbreaks, with special reference to Ebola. BMJ 2015; 351:h3740.
19. Henao-Restrepo AM, Camacho A, Longini IM, et al. Efficacy and effectiveness of an rVSV-vectored vaccine in preventing Ebola virus disease: final results from the Guinea ring vaccination, open-label, cluster-randomised trial (Ebola Ca Suffit!). Lancet 2017; 389:505-18.
20. Kennedy SB, Bolay F, Kieh M, et al. Phase 2 placebo-controlled trial of two vaccines to prevent Ebola in Liberia. N Engl J Med 2017; 377:1438-47.
21. Halperin SA, Arribas JR, Rupp R, et al. Six-month safety data of recombinant vesicular stomatitis virus-Zaire Ebola virus envelope glycoprotein vaccine in a phase 3 double-blind, placebo-controlled randomized study in healthy adults. J Infect Dis 2017; 215:1789-98.
22. Regules JA, Beigel JH, Paolino KM, et al. A recombinant vesicular stomatitis virus Ebola vaccine. N Engl J Med 2017; 376:330-41.
23. Agnandji ST, Huttner A, Zinser ME, et al. Phase 1 trials of rVSV Ebola vaccine in Africa and Europe. N Engl J Med 2016; 374:1647-60.
24. Rossen LM, Ahrens KA, Branum AM. Trends in risk of pregnancy loss among US women, 1990-2011. Paediatr Perinat Epidemiol 2018; 32:19-29.
25. Lane HC, Marston HD, Fauci AS. Conducting clinical trials in outbreak settings: points to consider. Clin Trials 2016; 13:92-5.
26. Meeting of the Strategic Advisory Group of Experts on immunization, October 2015-conclusions and recommendations. Wkly Epidemiol Rec 2015; 90:681-700.
27. Agnandji ST, Fernandes JF, Bache EB, et al. Safety and immunogenicity of rVSVΔG-ZEBOV-GP Ebola vaccine in adults and children in Lambarene, Gabon: a phase I randomised trial. PLoS Med 2017; 14:e1002402.
28. Gsell PS, Camacho A, Kucharski AJ, et al. Ring vaccination with rVSV-ZEBOV under expanded access in response to an outbreak of Ebola virus disease in Guinea, 2016: an operational and vaccine safety report. Lancet Infect Dis 2017; 17:1276-84.
29. Coltart CE, Johnson AM, Whitty CJ. Role of healthcare workers in early epidemic spread of Ebola: policy implications of prophylactic compared to reactive vaccination policy in outbreak prevention and control. BMC Med 2015; 13:1-10.
30. Gulland A. Ebola vaccine will be made available for emergency use. BMJ 2016; 532:i386.
31. Ebola virus disease (EVD) in West Africa: an extraordinary epidemic. Wkly Epidemiol Rec 2015; 90:89-96.
32. Meeting of the strategic advisory group of experts on immunization, April 2017-conclusions and recommendations. Wkly Epidemiol Rec 2017; 92:301-20.